related documents
- A phase II study of intravenous DX-8951f administered daily for five days every three weeks to patients with previously untreated metastatic gastric cancer. Conference Paper
- A phase II trial of the proteosome inhibitor PS-341 in patients with metastatic colorectal cancer Conference Paper
- A randomized controlled trial (RCT) of routine follow-up for early stage breast cancer: A comparison of primary care versus specialist care. Conference Paper
- A randomized phase I clinical and biologic study of two schedules of BAY 43-9006 in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): A National Cancer Institute of Cancer Clinical Trials Group Study. Conference Paper
- Assessment of quality of life (QOL) in MA.17, a randomized placebo-controlled trial of letrozole in postmenopausal women following five years of tamoxifen Conference Paper
- Association of young age and chemotherapy with psychosocial distress and health-related quality of life (HRQOL) during the first year after breast cancer (BC). Conference Paper
- Cancer patients and the Internet: A randomized controlled trial (RCT) evaluating an intervention to facilitate physician and patient information exchange from the Internet (I). Conference Paper
- Characteristics of out-of-pocket costs for cancer patients in Ontario, Canada Conference Paper
- Chemo-radiotherapy versus radiotherapy alone for nasopharyngeal carcinoma: A meta-analysis of 78 randomized controlled trials (RCTs) from English and non-English databases. Conference Paper
- Comparison of Outcomes of Phase II Studies and Subsequent Randomized Control Studies Using Identical Chemotherapeutic Regimens Conference Paper
- Comparison of outcomes of phase II trials (P2Ts) and subsequent randomized control trials (RCTs) using identical therapeutic regimens. Conference Paper
- Dexamethasone (dex) maintenance versus observation (obs) in patients with previously untreated multiple myeloma: A National Cancer Institute of Canada Clinical Trials Group Study: MY.7. Conference Paper
- Experience with sentinel lymph node biopsy for eyelid and conjunctival malignancies. Conference Paper
- Ontario Cancer Research Ethics Board (OCREB): A central research ethics board initiative. Conference Paper
- Patterns of trastuzumab (T) use in three Canadian provinces. Conference Paper
- Pegylated Liposomal Doxorubicin and Trastuzumab in HER-2 Overexpressing Metastatic Breast Cancer: A Multicenter Phase II Trial Conference Paper
- Phase I study of a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 4 (TRAIL-R1) in subjects with advanced solid malignancies or non-Hodgkin's lymphoma (NHL) Conference Paper
- Phase II study of erlotinib (OSI 774) in women with recurrent or metastatic endometrial cancer: NCICCTG IND-148. Conference Paper
- Practitioner feedback an clinical practice guidelines developed by Cancer Care Ontario's Lung Disease Site Group: Extending the circle of involvement. Conference Paper
- Prognostic factors in early stage head and neck squamous cell carcinoma (HNSCC) patients in a prospective clinical trial. Conference Paper
- Prognostication using serum levels of components of the folate metabolic pathway in patients (PTS) treated with capecitabine for advanced colorectal cancer (ACRC). Conference Paper
- Retrospective analysis of treatment practices for elderly cancer patients (Pts) in Ontario, Canada Conference Paper
- Slow intravenous infusion of PV701, an oncolytic virus: Final results of a phase I study Conference Paper
- Supportive care in cancer. Who does what? Conference Paper
- The intensity of CEACAM-1 expression in melanoma patients and the timing of treatment with recombinant human interferon & 2b showed correlation with survival. Conference Paper
- Thromboembolism (TE) in children with acute lymphoblastic leukemia (ALL) treated on Dana Farber Cancer Institute (DFCI) protocols: Effect of dose and type (prednisone versus dexamethasone) of steroids used. Conference Paper
- Tolerability of the Intergroup 0099 regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status. Conference Paper
- Zoledronic acid reduces the need for radiation to bone in patients with breast or prostate cancer metastatic to bone: A survival-adjusted cumulative incidence analysis. Conference Paper